SANFILIPPO, GIOVANNA ROBERTA
SANFILIPPO, GIOVANNA ROBERTA
Universita' degli Studi di MILANO
Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma Group
2025 L. D'Ambrosio, M. Sbaraglia, A. Merlini, M. Rabino, G. Grignani, V. Appolloni, G. Badalamenti, G.G. Baldi, E. Bellan, M. Benelli, A.F. Bertuzzi, R. Biagini, G. Bianchi, A. Boglione, A. Brunello, D.A. Campanacci, F. Cananzi, P.G. Casali, B. Casini, M. Cesari, B. Chiusole, C. Cristalli, A. De Vita, E. Di Blasi, F. Fagioli, V. Fausti, V. Ferraresi, A.M. Frezza, E. Fumagalli, M. Gambarotti, C. Giani, A. Gronchi, M. Grassi, T. Ibrahim, A. Ivanescu, G. Ignazzi, L. Incorvaia, A. Linari, R. Luksch, A. Marrari, A. Mazzocca, G.M. Milano, C. Morosi, M. Nannini, P. Navarria, E. Palassini, E. Palmerini, F. Paloschi, M.A. Pantaleo, S. Pasquali, V. Pavese, E. Pozzo, V. Quagliuolo, M. Quirino, R. Sanfilippo, F. Santoro, K. Scotlandi, M. Serra, E. Setola, S. Strippoli, S. Tafuto, E. Tirtei, S. Vanni, B. Vincenzi, R. Maestro, A.P. Dei Tos, S. Stacchiotti
Long-term disease stability with bicalutamide in a man with aggressive angiomyxoma: case report and state of art
2024 A. Franza, E. Gusmaroli, C. Fabbroni, R. Vigorito, S. Pasquali, P.G. Casali, R.G. Sanfilippo
New targeted therapies in liposarcoma: state of art and future perspectives
2024 A. Franza, C. Fabbroni, S. Pasquali, P.G. Casali, R. Sanfilippo
Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG)
2024 A. Gronchi, E. Palmerini, V. Quagliuolo, J. Martin Broto, A. Lopez Pousa, G. Grignani, A. Brunello, J. Blay, O. Tendero, R. Diaz Beveridge, V. Ferraresi, I. Lugowska, S. Pizzamiglio, P. Verderio, V. Fontana, D.M. Donati, E. Palassini, R. Sanfilippo, G. Bianchi, A. Bertuzzi, C. Morosi, S. Pasquali, S. Stacchiotti, S. Bagué, J.M. Coindre, R. Miceli, A.P. Dei Tos, P.G. Casali
Mechanism of efficacy of trabectedin against myxoid liposarcoma entails detachment of the FUS-DDIT3 transcription factor from its DNA binding sites
2024 I. Craparotta, L. Mannarino, R. Zadro, S. Ballabio, S. Marchini, G. Pavesi, M. Russo, S.L. Renne, M. Meroni, M. Ponzo, E. Bello, R. Sanfilippo, P.G. Casali, M. D'Incalci, R. Frapolli
Low-Grade Uterine Leiomyosarcoma Is Highly Sensitive to Hormonal Treatment
2023 R. Sanfilippo, M. Sbaraglia, C. Fabbroni, S. Croce, I. Ray-Coquard, F. Guermazi, B. Paolini, F. Blanc-Durand, A. Lecesne, V. Chiappa, A.P. Dei Tos, P.G. Casali
Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis
2022 E. Palmerini, R. Sanfilippo, G. Grignani, A. Buonadonna, A. Romanini, G. Badalamenti, V. Ferraresi, B. Vincenzi, A. Comandone, A. Pizzolorusso, A. Brunello, F. Gelsomino, T. De Pas, T. Ibrahim, L. Gurrieri, F. Grosso, F. Zanelli, M.A. Pantaleo, L. Milesi, L. Ciuffreda, V. Ferrari, E. Marchesi, I. Quattrini, A. Righi, E. Setola, E. Carretta, P.G. Casali, P. Picci, S. Ferrari
Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry
2022 B. Vincenzi, A. Napolitano, A. Comandone, R. Sanfilippo, S. Celant, P.P. Olimpieri, S. Di Segni, P. Russo, P.G. Casali
Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation
2021 V. Zuco, S. Pasquali, M. Tortoreto, S. Brich, S. Percio, G.P. Dagrada, C. Colombo, R. Sanfilippo, C. Lauricella, M. Gounder, R. El Bezawy, M. Barisella, A.P. Dei Tos, P.G. Casali, A. Gronchi, S. Stacchiotti, N. Zaffaroni
Impact of pathological stratification on the clinical outcomes of advanced well‐differentiated/dedifferentiated liposarcoma treated with trabectedin
2021 C. Fabbroni, G. Fuca, F. Ligorio, E. Fumagalli, M. Barisella, P. Collini, C. Morosi, A. Gronchi, A.P.D. Tos, P.G. Casali, R. Sanfilippo
Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma
2021 L. Mannarino, I. Craparotta, S. Ballabio, R. Frapolli, M. Meroni, E. Bello, N. Panini, M. Callari, R. Sanfilippo, P.G. Casali, M. Barisella, C. Fabbroni, S. Marchini, M. D'Incalci
Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors
2020 R. Sanfilippo, C. Fabbroni, G. Fucà, E. Fumagalli, C. Morosi, M. Sbaraglia, A. Gronchi, P. Collini, A.P. Dei Tos, P.G. Casali
Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers
2020 G. Fucà, C. Fabbroni, R. Mancari, S. Manglaviti, G. Bogani, E. Fumagalli, R. Bertulli, C. Morosi, P. Collini, F. Raspagliesi, N. Colombo, P.G. Casali, R. Sanfilippo
Combination of PPARg agonist pioglitazone and trabectedin induce adipocyte differentiation to overcome trabectedin resistance in myxoid liposarcomas
2019 R. Frapolli, E. Bello, M. Ponzo, I. Craparotta, L. Mannarino, S. Ballabio, S. Marchini, L. Carrassa, P. Ubezio, L. Porcu, S. Brich, R. Sanfilippo, P.G. Casali, A. Gronchi, S. Pilotti, M. D'Incalci
Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma : A Multicenter, International, Retrospective Study
2019 G. Fucà, N. Hindi, I. Ray-Coquard, V. Colia, A.P. Dei Tos, J. Martin-Broto, M. Brahmi, P. Collini, D. Lorusso, F. Raspagliesi, M.A. Pantaleo, B. Vincenzi, E. Fumagalli, A. Gronchi, P.G. Casali, R. Sanfilippo
Role of chemotherapy, VEGFR inhibitors and mTOR Inhibitors in advanced Perivascular Epithelioid Cell Tumours (PEComas)
2019 R. Sanfilippo, R.L. Jones, J. Blay, A. Le Cesne, S. Provenzano, G. Antoniou, O. Mir, G. Fucà, E. Fumagalli, R. Bertulli, S. Stacchiotti, M. Brahmi, F. Grosso, A. Dufresne, N. Hindi, M. Sbaraglia, A. Gronchi, P. Collini, A.P. Dei Tos, P.G. Casali
Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups
2019 A. Gronchi, N. Hindi, J. Cruz, J.-. Blay, A. Lopez-Pousa, A. Italiano, R. Alvarez, A. Gutierrez, I. Rincon, C. Sangalli, J.L. Perez Aguiar, J. Romero, C. Morosi, M.P. Sunyach, R. Sanfilippo, C. Romagosa, D. Ranchere-Vince, A.P. Dei Tos, P.G. Casali, J. Martin-Broto
Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients—A propensity score analysis
2019 E. Nizri, M. Fiore, C. Colombo, S. Radaelli, D. Callegaro, R. Sanfilippo, C. Sangalli, P. Collini, C. Morosi, S. Stacchiotti, P.G. Casali, A. Gronchi
Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma
2017 V. Colia, M. Fiore, S. Provenzano, E. Fumagalli, R. Bertulli, C. Morosi, A.P. Dei Tos, M. Barisella, A. Gronchi, P.G. Casali, R. Sanfilippo
High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma
2017 V. Colia, E. Fumagalli, S. Provenzano, R. Bertulli, S. Stacchiotti, C. Morosi, P. Collini, A. Gronchi, P.G. Casali, R. Sanfilippo